ABBV AbbVie Inc.

Healthcare · Drug Manufacturers - General

3 · Weak Momentum 9.0 · Strong At risk 12y streak

264.34

-0.29%

About the company

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Website Annual reports (10-K)

2.62%

194.93%

6.92

467.1B

74.46

3.55

230.36

52-week range

264

low 191 high 269

Dividend deep dive

AbbVie Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. The company currently offers a dividend yield of 2.62%, which is below its 5-year average of 3.8%. The company has a dividend rating score of 3.0. Its momentum score is 9.0, indicating a strong recent price trend, while its value score is 3.3, suggesting it may be considered rich based on certain metrics.

Dividend history

AbbVie has consistently increased its dividend for 12 consecutive years, earning it a "Contender" tier status. Over the past three years, the dividend has grown at a compound annual growth rate (CAGR) of 5.17%, while the five-year CAGR stands at 6.81%. The company pays quarterly dividends in January, April, July, and October. Annual dividends per share have increased from USD 1.68 in 2014 to USD 5.92 in 2023, with a projected USD 6.56 for 2025 based on the provided data. This growth has resulted in a dividend doubling time of 10.6 years, at a CAGR of 6.81%.

Dividend safety

The dividend safety status for AbbVie is currently designated as "at_risk." The company's payout ratio is 195.48%, indicating the annual dividend of USD 6.92 is not fully covered by earnings per share of USD 3.54.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 21 Sep 2026 · Information, not financial advice.